A Phase 3 interventional study of pemetrexed and docetaxel in Non-Small Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 20 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-08-10.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 21 open to participants now, 32 under way, 11 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.
Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 37th largest by enrollment of the 223 interventional ones that give a count, is one of 12 that started in 2007, is one of 44 in phase 3, and was the 59th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →21 of the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Belgium, Brazil and 17 more countries
Ages 18+
Guangzhou Medical University · Sites in China
Ages 18–75
Second Affiliated Hospital of Nanchang University · Sites in China
Ages 18–85
Shanghai Chest Hospital · Sites in China
Ages 18+
Taipei Veterans General Hospital, Taiwan · Sites in Taiwan
Ages 20+
By country, each count listing its studies:
Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
227 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 148 · Phase 3 47 · Phase 4 8
First in 2001; this study’s year is marked. 12 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 260 is above the median of 62 across 6,023 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 64 across the 223 interventional studies. Of the 161 that completed or were terminated, 89 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 227 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company: 6 open now, 20 under way, 6 of them phase 3. Of 121 finished, 81 (67%) have results posted.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 30th largest by enrollment of the 139 interventional ones that give a count, is one of 9 that started in 2007, is one of 25 in phase 3, and was the 53rd registered.
Eli Lilly and Company’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
7 of the studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04585490Phase 3Stanford UniversityAdaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC | 2026-12 |
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT03178552Phase 3Hoffmann-La RocheA Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | 2027-06-30 |
| NCT05805631Taipei Veterans General Hospital, TaiwanIntrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC | 2026-12-31 |
| NCT06440954Hunan Province Tumor HospitalEfficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Eli Lilly and Company’s 147 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the combination of pemetrexed and carboplatin with the combination of docetaxel and carboplatin in terms of survival without Grade 3 or 4 toxicity in previously untreated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: pemetrexed 500 milligrams per square meter (mg/m\^2), intravenous (IV), every (q) 21 days x 6 cycles maximum Drug: carboplatin Area Under the Curve (AUC) 5 milligram\*minute/milliLiter (mg\*min/mL), IV, q 21 days x 6 cycles maximum
Drug: pemetrexed · Drug: carboplatin
Drug: docetaxel 75 mg/m\^2, IV, q 21 days x 6 cycles maximum Drug: carboplatin AUC 5 mg\*min/mL, IV, q 21 days x 6 cycles maximum
Drug: docetaxel · Drug: carboplatin
500 mg/m\^2, IV, q 21 days x 6 cycles maximum
Also known as: LY231514, Alimta
75 mg/m\^2, IV, q 21 days x 6 cycles maximum
AUC 5 mg\*min/mL, IV, q 21 days x 6 cycles maximum
Survival Without Grade 3 or 4 Toxicity
Defined as the time from date of randomization to first date of a Grade 3 or 4 treatment-emergent adverse event (TEAE; as graded by the National Cancer Institute Common Terminology Criteria for Adverse Events \[CTCAE\], version 3.0) or death due to any cause. Grade 3 TEAE: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated. Grade 4 TEAE: Life-threatening consequences; urgent intervention indicated. Participants who were alive without experiencing Grade 3 or 4 toxicity were censored at the date of last contact.
Time frame: Baseline to until 218 events (defined as death or Grade 3 or 4 toxicity) have been observed (up to 33.3 months).
Overall Survival (OS)
OS is the duration from enrollment to death. For participants who are alive, OS is censored at the last contact.
Time frame: Baseline to until 218 events (defined as death or Grade 3 or 4 toxicity) have been observed (up to 33.3 months).
Progression-free Survival (PFS)
Defined as the time from date of first dose to the first observation of disease progression (PD), or death due to any cause.
Time frame: Baseline to until 218 events (defined as death or Grade 3 or 4 toxicity) have been observed (up to 33.3 months).
Percentage of Participants With Tumor Response (Response Rate)
Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response (CR)=disappearance of all target lesions; Partial Response (PR)=at least a 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD)=at least a 20% increase in sum of longest diameter of target lesions; Stable Disease (SD)=small changes not meeting above criteria. Response rate (%)=Number of participants with CR+PR/Number of participants analyzed \*100. Disease Control rate=Number of participants with SD+PR+CR/Number of participants analyzed \*100.
Time frame: Baseline to until 218 events (defined as death or Grade 3 or 4 toxicity) have been observed (up to 33.3 months).
Survival Without Clinically Important Grade 3 or 4 Toxicity
Survival without Grade 3 or 4 toxicity is the time from date of randomization to the first date of the following clinically important Grade 3 or 4 TEAEs graded by the Common Terminology Criteria for Adverse Events \[CTCAE\], version 3.0: neutropenia (lasting \>5 days), febrile neutropenia, documented infections related to neutropenia, anemia, thrombocytopenia, fatigue, nausea, vomiting, diarrhea, stomatitis, and neurosensory events; or death due to any cause. Participants who were alive without experiencing Grade 3 or 4 toxicity were censored for this analysis at the date of last contact.
Time frame: Baseline to until 218 events (defined as death or Grade 3 or 4 toxicity) have been observed (up to 33.3 months).
Survival Without Grade 4 Toxicity
Survival without Grade 4 toxicity is the time from the date of randomization to the first date of a Grade 4 TEAE or death due to any cause. Participants who are alive without experiencing Grade 4 toxicity will be censored for this analysis at the date of last contact.
Time frame: Baseline to until 218 events (defined as death or Grade 4 toxicity) have been observed (up to 33.3 months).
Number of Participants With Adverse Events (AEs)
Summaries of serious AEs (SAEs) and all other non-serious AEs are located in the Reported Adverse Event Module.
Time frame: Baseline to until 218 events (defined as death or Grade 3 or 4 toxicity) have been observed (up to 33.3 months).
Duration of Response
The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause. Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. CR=disappearance of all target lesions; PR=at least a 30% decrease in sum of longest diameter of target lesions.
Time frame: Baseline to until 218 events (defined as death or Grade 3 or 4 toxicity) have been observed (up to 33.3 months).
| Milestone | Pemetrexed Plus Carboplatin | Docetaxel Plus Carboplatin |
|---|---|---|
| Started | 128 | 132 |
| Received at least 1 dose of study drug | 118 | 127 |
| Qualified intent-to-treat (q-itt) | 106 | 105 |
| Completed | 27 | 29 |
| Not completed | 101 | 103 |
| Withdrew: Death | 84 | 81 |
| Withdrew: Lost to follow-up | 6 | 10 |
| Withdrew: Physician decision | 4 | 1 |
| Withdrew: Withdrawal by subject | 7 | 11 |
Defined as the time from date of randomization to first date of a Grade 3 or 4 treatment-emergent adverse event (TEAE; as graded by the National Cancer Institute Common Terminology Criteria for Adverse Events \[CTCAE\], version 3.0) or death due to any cause. Grade 3 TEAE: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated. Grade 4 TEAE: Life-threatening consequences; urgent intervention indicated. Participants who were alive without experiencing Grade 3 or 4 toxicity were censored at the date of last contact.
| months | Pemetrexed Plus Carboplatin | Docetaxel Plus Carboplatin |
|---|---|---|
| Survival Without Grade 3 or 4 Toxicity | 3.2 (2.1 to 3.7) | 0.7 (0.5 to 1.2) |
OS is the duration from enrollment to death. For participants who are alive, OS is censored at the last contact.
| months | Pemetrexed Plus Carboplatin | Docetaxel Plus Carboplatin |
|---|---|---|
| Overall Survival (OS) | 14.9 (12.2 to 19.0) | 14.7 (10.8 to 19.8) |
Defined as the time from date of first dose to the first observation of disease progression (PD), or death due to any cause.
| months | Pemetrexed Plus Carboplatin | Docetaxel Plus Carboplatin |
|---|---|---|
| Progression-free Survival (PFS) | 5.8 (4.8 to 6.4) | 6.0 (4.8 to 6.6) |
Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response (CR)=disappearance of all target lesions; Partial Response (PR)=at least a 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD)=at least a 20% increase in sum of longest diameter of target lesions; Stable Disease (SD)=small changes not meeting above criteria. Response rate (%)=Number of participants with CR+PR/Number of participants analyzed \*100. Disease Control rate=Number of participants with SD+PR+CR/Number of participants analyzed \*100.
| percentage of participants | Pemetrexed Plus Carboplatin | Docetaxel Plus Carboplatin |
|---|---|---|
| Tumor Response Rate | 34.0 (25.0 to 43.8) | 23.1 (15.4 to 32.4) |
| Disease Control Rate | 74.5 (65.1 to 82.5) | 64.4 (54.4 to 73.6) |
| Complete Response | 0.9 (0.0 to 5.1) | 0 (0 to 3.5) |
| Partial Response | 33.0 (24.2 to 42.8) | 23.1 (15.4 to 32.4) |
| Stable Disease | 40.6 (31.1 to 50.5) | 41.3 (31.8 to 51.4) |
| Progressive Disease | 16.0 (9.6 to 24.4) | 17.3 (10.6 to 26.0) |
| Unknown | 9.4 (4.6 to 16.7) | 18.3 (11.4 to 27.1) |
The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause. Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. CR=disappearance of all target lesions; PR=at least a 30% decrease in sum of longest diameter of target lesions.
| months | Pemetrexed Plus Carboplatin | Docetaxel Plus Carboplatin |
|---|---|---|
| Duration of Response | 5.5 (4.0 to 8.1) | 5.4 (4.4 to 6.7) |
Survival without Grade 3 or 4 toxicity is the time from date of randomization to the first date of the following clinically important Grade 3 or 4 TEAEs graded by the Common Terminology Criteria for Adverse Events \[CTCAE\], version 3.0: neutropenia (lasting \>5 days), febrile neutropenia, documented infections related to neutropenia, anemia, thrombocytopenia, fatigue, nausea, vomiting, diarrhea, stomatitis, and neurosensory events; or death due to any cause. Participants who were alive without experiencing Grade 3 or 4 toxicity were censored for this analysis at the date of last contact.
| months | Pemetrexed Plus Carboplatin | Docetaxel Plus Carboplatin |
|---|---|---|
| Survival Without Clinically Important Grade 3 or 4 Toxicity | 3.6 (3.0 to 8.0) | 1.3 (1.1 to 1.9) |
Survival without Grade 4 toxicity is the time from the date of randomization to the first date of a Grade 4 TEAE or death due to any cause. Participants who are alive without experiencing Grade 4 toxicity will be censored for this analysis at the date of last contact.
| participants | Pemetrexed Plus Carboplatin | Docetaxel Plus Carboplatin |
|---|---|---|
| Survival Without Grade 4 Toxicity | 12.2 (8.4 to 14.9) | 2.0 (1.6 to 3.8) |
Summaries of serious AEs (SAEs) and all other non-serious AEs are located in the Reported Adverse Event Module.
| participants | Pemetrexed Plus Carboplatin | Docetaxel Plus Carboplatin |
|---|---|---|
| Non-Serious Adverse Events (AEs) | 94 | 100 |
| Serious Adverse Events (SAEs) | 28 | 35 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pemetrexed Plus Carboplatin | — | 28/106 (26.4%) | 94/106 (88.7%) |
| Docetaxel Plus Carboplatin | — | 35/105 (33.3%) | 100/105 (95.2%) |
| Event | Pemetrexed Plus Carboplatin | Docetaxel Plus Carboplatin |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 0/106 | 9/105 |
| NeutropeniaBlood and lymphatic system disorders | 2/106 | 8/105 |
| PneumoniaInfections and infestations | 5/106 | 7/105 |
| LeukopeniaBlood and lymphatic system disorders | 1/106 | 3/105 |
| Atrial fibrillationCardiac disorders | 0/106 | 3/105 |
| DiarrhoeaGastrointestinal disorders | 0/106 | 3/105 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/106 | 3/105 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/106 | 3/105 |
| ThrombocytopeniaBlood and lymphatic system disorders | 3/106 | 2/105 |
| VomitingGastrointestinal disorders | 1/106 | 2/105 |
| Event | Pemetrexed Plus Carboplatin | Docetaxel Plus Carboplatin |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 40/106 | 74/105 |
| LeukopeniaBlood and lymphatic system disorders | 33/106 | 56/105 |
| AlopeciaSkin and subcutaneous tissue disorders | 10/106 | 45/105 |
| NauseaGastrointestinal disorders | 43/106 | 37/105 |
| AnaemiaBlood and lymphatic system disorders | 36/106 | 18/105 |
| DiarrhoeaGastrointestinal disorders | 12/106 | 30/105 |
| Decreased appetiteMetabolism and nutrition disorders | 27/106 | 30/105 |
| LymphopeniaBlood and lymphatic system disorders | 14/106 | 25/105 |
| FatigueGeneral disorders | 13/106 | 21/105 |
| VomitingGastrointestinal disorders | 18/106 | 19/105 |
| Age Continuous(years) | Pemetrexed Plus Carboplatin | Docetaxel Plus Carboplatin | Total |
|---|---|---|---|
| Mean | 59.6 ± 10.0 | 59.2 ± 10.7 | 59.4 ± 10.3 |
| Sex: Female, Male(Participants) | Pemetrexed Plus Carboplatin | Docetaxel Plus Carboplatin | Total |
|---|---|---|---|
| Female | 42 | 55 | 97 |
| Male | 64 | 50 | 114 |
| Region of Enrollment(participants) | Pemetrexed Plus Carboplatin | Docetaxel Plus Carboplatin | Total |
|---|---|---|---|
| Taiwan | 3 | 9 | 12 |
| Mexico | 17 | 22 | 39 |
| Brazil | 35 | 25 | 60 |
| Australia | 10 | 14 | 24 |
| China | 20 | 17 | 37 |
| Korea, Republic of | 21 | 18 | 39 |
| Smoking Status(participants) | Pemetrexed Plus Carboplatin | Docetaxel Plus Carboplatin | Total |
|---|---|---|---|
| Never Smoking | 34 | 41 | 75 |
| Ever Smoking but Quit | 61 | 53 | 114 |
| Currently Smoking | 11 | 11 | 22 |
| Histology(participants) | Pemetrexed Plus Carboplatin | Docetaxel Plus Carboplatin | Total |
|---|---|---|---|
| Adenocarcinoma, lung | 10 | 11 | 21 |
| Adenocarcinoma, not otherwise specified | 80 | 80 | 160 |
| Large cell carcinoma, lung | 10 | 9 | 19 |
| Carcinoma, lung | 6 | 5 | 11 |
The record gives a start of Oct 2007, a primary completion of Jul 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2011, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pemetrexed
Carcinoma, Non-Small-Cell Lung →